Citations

Showing 10 of 108083 citations.

Developing the Ideal Barrett’s Esophagus Screening Program: Is it Time for Universal Screening?
Zhang, Han , Kahn, Allon

Mayo Clinic

Foregut: The Journal of the American Foregut Society | February 24, 2023 | Volume: 3 | Issue: 1 | Pages: 107-113

10.1177/26345161231156150 Get It

Esophageal adenocarcinoma (EAC) is rising in incidence and has a poor 5-year survival. Decades of targeted screening for Barrett’s esophagus (BE), the precursor to EAC, have not appreciably reduced EAC incidence. Here, we review the drawbacks of the current screening paradigm, including overreliance on GERD symptoms and sedated upper endoscopy. We debate the merits of a universal BE screening program. We propose an ideal BE screening strategy combining novel risk stratification models and non-invasive screening techniques to expand selective screening to patients without GERD, but at elevated risk for BE.
Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists
Wenzler, Eric , Maximos, Mira , Asempa, Tomefa E. , Biehle, Lauren , Hirsch, Elizabeth B. , Hirsch, Elizabeth B , Schuetz, Audrey N.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | February 24, 2023 | Volume: 43 | Issue: 4 | Pages: 264-278

10.1002/phar.2781 | PMID 36825480 Get It

Abstract Antimicrobial susceptibility testing (AST) is a critical function of the clinical microbiology laboratory and is essential for optimizing care of patients with infectious diseases, monitoring antimicrobial resistance (AMR) trends, and informing public health initiatives. Several methods are available for performing AST including broth microdilution, agar dilution, and disk diffusion. Technological advances such as the development of commercial automated susceptibility testing platforms and the advent of rapid diagnostic tests have improved the rapidity, robustness, and clinical application of AST. Numerous accrediting and regulatory agencies are involved in the process of AST and setting and revising breakpoints, including the U.S. Food and Drug Administration and the Clinical and Laboratory Standards Institute. Challenges to optimizing AST include the emergence of new resistance mechanisms, the development of new antimicrobial agents, and generation of new data requiring updates and revisions to established methods and breakpoints. Together, the challenges in AST methods and their interpretation create important opportunities for well‐informed clinicians to improve patient outcomes and provide value to antimicrobial stewardship programs, especially in the setting of rapidly changing and increasing AMR. Addressing AST challenges will involve continued development of new technologies along with collaboration between clinicians and the laboratory to facilitate optimal antimicrobial use, combat the increasing burden of AMR, and inform the development of novel antimicrobials. This updated primer serves to reinforce important principles of AST, and to provide guidance on their implementation and optimization.
Educational Scoring System in Laparoscopic Cholecystectomy: Is It the Right Time to Standardize?
Reitano, Elisa , Famularo, Simone , Dallemagne, Bernard , Mishima, Kohei , Perretta, Silvana , Riva, Pietro , Addeo, Pietro , Asbun, Horacio J. , Conrad, Claudius , Demartines, Nicolas , Giménez, Mariano , Hogg, Melissa E. , Lin, Charles, Marescaux, Jacques , Memeo, Riccardo , Vix, Michel , Wang, Xiaoying , Mutter, Didier , Memeo, Riccardo , Marescaux, Jacques , Vix, Michel , Demartines, N , Fuks, David , Martinie, John B. , Soubrane, Olivier

Mayo Clinic

Medicina | February 24, 2023 | Volume: 59 | Issue: 3 | Pages: 446

10.3390/medicina59030446 | PMID 36984446 Get It

Background and Objectives: Laparoscopic cholecystectomy (LC) is one of the most performed surgeries worldwide. Procedure difficulty and patient outcomes depend on several factors which are not considered in the current literature, including the learning curve, generating confusing and subjective results. This study aims to create a scoring system to calculate the learning curve of LC based on hepatobiliopancreatic (HPB) experts’ opinions during an educational course. Materials and Methods: A questionnaire was submitted to the panel of experts attending the HPB course at Research Institute against Digestive Cancer-IRCAD (Strasbourg, France) from 27–29 October 2022. Experts scored the proposed variables according to their degree of importance in the learning curve using a Likert scale from 1 (not useful) to 5 (very useful). Variables were included in the composite scoring system only if more than 75% of experts ranked its relevance in the learning curve assessment ≥4. A positive or negative value was assigned to each variable based on its effect on the learning curve. Results: Fifteen experts from six different countries attended the IRCAD HPB course and filled out the questionnaire. Ten variables were finally included in the learning curve scoring system (i.e., patient body weight/BMI, patient previous open surgery, emergency setting, increased inflammatory levels, presence of anatomical bile duct variation(s), and appropriate critical view of safety (CVS) identification), which were all assigned positive values. Minor or major intraoperative injuries to the biliary tract, development of postoperative complications related to biliary injuries, and mortality were assigned negative values. Conclusions: This is the first scoring system on the learning curve of LC based on variables selected through the experts’ opinions. Although the score needs to be validated through future studies, it could be a useful tool to assess its efficacy within educational programs and surgical courses.
Applications of Microwaves in Medicine Leveraging Artificial Intelligence: Future Perspectives
Gopalakrishnan, Keerthy, Adhikari, Aakriti , Pallipamu, Namratha, Singh, Mansunderbir, Nusrat, Tasin , Gaddam, Sunil , Samaddar, Poulami , Rajagopal, Anjali , Cherukuri, Akhila Sai Sree, Yadav, Anmol, Manga, Shreya Sai, Damani, Devanshi N. , Shivaram, Suganti, Dey, Shuvashis , Roy, Sayan , Mitra, Dipankar , Arunachalam, Shivaram P. , Arunachalam, S P , Dey, Shuvashis , Roy, Sayan , Shivaram, Suganti

Mayo Clinic

Electronics | February 24, 2023 | Volume: 12 | Issue: 5 | Pages: 1101

10.3390/electronics12051101 Get It

Microwaves are non-ionizing electromagnetic radiation with waves of electrical and magnetic energy transmitted at different frequencies. They are widely used in various industries, including the food industry, telecommunications, weather forecasting, and in the field of medicine. Microwave applications in medicine are relatively a new field of growing interest, with a significant trend in healthcare research and development. The first application of microwaves in medicine dates to the 1980s in the treatment of cancer via ablation therapy; since then, their applications have been expanded. Significant advances have been made in reconstructing microwave data for imaging and sensing applications in the field of healthcare. Artificial intelligence (AI)-enabled microwave systems can be developed to augment healthcare, including clinical decision making, guiding treatment, and increasing resource-efficient facilities. An overview of recent developments in several areas of microwave applications in medicine, namely microwave imaging, dielectric spectroscopy for tissue classification, molecular diagnostics, telemetry, biohazard waste management, diagnostic pathology, biomedical sensor design, drug delivery, ablation treatment, and radiometry, are summarized. In this contribution, we outline the current literature regarding microwave applications and trends across the medical industry and how it sets a platform for creating AI-based microwave solutions for future advancements from both clinical and technical aspects to enhance patient care.
Recurrence, Reoperation, Pregnancy Rates, and Risk Factors for Recurrence after Ovarian Endometrioma Surgery: Long-Term Follow-Up of 756 Women
Choi, Su Hyeon , Kim, Sujin , Lee, Si Won , Won, Seyeon , Shim, So Hyun , Lee, Nara , Kim, Mi Kyoung , Jung, Yong Wook , Seong, Seok Ju , Kim, Mi‐La

Mayo Clinic

Yonsei Medical Journal | February 24, 2023 | Volume: 64 | Issue: 3 | Pages: 204

10.3349/ymj.2022.0278 | PMID 36825347 Get It

Gastroblastoma of the Pylorus: A Case Report and Review of the Literature
McCammon, Nathan , Dunn, Andrew , Graham, Rondell P. , McHugh, Jonathan B. , Lamps, Laura, Bresler, Scott C. , Cole, Thomas, Rottmann, Douglas , Graham, Rondell P , Cole, Thomas

Mayo Clinic

International Journal of Surgical Pathology | February 24, 2023 | Volume: 31 | Issue: 8 | Pages: 1516-1521

10.1177/10668969231157310 | PMID 36823781 Get It

Gastroblastoma is an extremely rare biphasic tumor that typically occurs in the stomach in patients between the ages of 10 and 30. Only 16 cases have been reported previously. These tumors are important to diagnose and distinguish from more aggressive neoplasms; although numbers are small, prognosis appears excellent overall with complete excision, with only occasional metastasis and/or local recurrence. We report a case of gastroblastoma in a 26-year-old male arising from the pylorus and extending through the first and second portions of the duodenum. This is the first case to be reported from this specific location.
Biomechanical Analysis of Multilevel Posterior Cervical Spinal Fusion Constructs
Murphy, T. P. , Le, Anthony H. , Fredericks, Donald R. , Schlaff, Cody D. , Holm, Erik B., Sebastian, Arjun S. , Pisano, Alfred J. , Helgeson, Melvin D. , Wagner, Scott C. , Murphy, Timothy P., Colantonio, Donald F.

Mayo Clinic

Clinical Spine Surgery | February 24, 2023 | Volume: 36 | Issue: 5 | Pages: E212-E217

10.1097/bsd.0000000000001429 | PMID 36823698 Get It

Study Design: Controlled Laboratory Study Objective: To compare multilevel posterior cervical fusion (PCF) constructs stopping at C7, T1, and T2 under cyclic load to determine the range of motion (ROM) between the lowest instrumented level and lowest instrumented-adjacent level (LIV-1). Summary of Background Data: PCF is a mainstay of treatment for various cervical spine conditions. The transition between the flexible cervical spine and rigid thoracic spine can lead to construct failure at the cervicothoracic junction. There is little evidence to determine the most appropriate level at which to stop a multilevel PCF. Methods: Fifteen human cadaveric cervicothoracic spines were randomly assigned to 1 of 3 treatment groups: PCF stopping at C7, T1, or T2. Specimens were tested in their native state, following a simulated PCF, and after cyclic loading. Specimens were loaded in flexion-extension), lateral bending, and axial rotation. Three-dimensional kinematics were recorded to evaluate ROM. Results: The C7 group had greater flexion-extension motion than the T1 and T2 groups following instrumentation (10.17±0.83 degree vs. 2.77±1.66 degree and 1.06±0.55 degree, P <0.001), and after cyclic loading (10.42±2.30 degree vs. 2.47±0.64 degree and 1.99±1.23 degree, P <0.001). There was no significant difference between the T1 and T2 groups. The C7 group had greater lateral bending ROM than both thoracic groups after instrumentation (8.81±3.44 degree vs. 3.51±2.52 degree, P =0.013 and 1.99±1.99 degree, P =0.003) and after cyclic loading. The C7 group had greater axial rotation motion than the thoracic groups (4.46±2.27 degree vs. 1.26±0.69 degree, P =0.010; and 0.73±0.74 degree, P =0.003) following cyclic loading. Conclusion: Motion at the cervicothoracic junction is significantly greater when a multilevel PCF stops at C7 rather than T1 or T2. This is likely attributable to the transition from a flexible cervical spine to a rigid thoracic spine. Although this does not account for in vivo fusion, surgeons should consider extending multilevel PCF constructs to T1 when feasible. Level of Evidence: Not applicable.
High-Pitch Multienergy Coronary CT Angiography in Dual-Source Photon-Counting Detector CT Scanner at Low Iodinated Contrast Dose
Dunning, Chelsea A. S. , Tandon, Yasmeen K. , Ahmed, Zaki, Larson, Nicholas B. , Thorne, Jamison E. , Williamson, Eric E. , Larson, Nicholas B , Rajiah, Prabhakar , Rajendran, Kishore , Collins, Jeremy D. , Fletcher, Joel G. , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Investigative Radiology | February 23, 2023 | Volume: 58 | Issue: 9 | Pages: 681-690

10.1097/rli.0000000000000961 | PMID 36822655 Get It

Objectives The aim of this study was to evaluate the high-helical pitch, multienergy (ME) scanning mode of a clinical dual-source photon-counting detector (PCD) computed tomography (CT) and the benefit of virtual monoenergetic images (VMIs) for low-contrast-dose coronary CT angiography (CTA). Materials and Methods High-pitch (3.2) ME coronary CTA was performed in PCD-CT in 27 patients using low contrast dose (30 mL of iohexol 350 mg/mL) and in 26 patients at routine contrast dose (60 mL). Low-energy-threshold 120 kV images (also known as T3D images) and 50 kiloelectron volts (50 keV) and 100 kiloelectron volts (100 keV) VMIs were reconstructed using a 1024 × 1024 matrix and 0.6-mm slices. The CT numbers, noise, and contrast-to-noise ratio (CNR) were measured in the ascending aorta (AA), left main coronary artery (LMCA), and distal left anterior descending (LAD) artery. Confidence in grading luminal stenosis with calcific plaque, noncalcific plaque, and stent was evaluated by 2 independent readers on a 0–100 scale (0 the lowest), and a CAD-RADS score was assigned. Image contrast enhancement, sharpness, noise, artifacts, and overall image quality were rated using a 5-point ordinal scale (1 the lowest). Results The radiation doses (CTDI) in low- and routine-contrast cohorts were 2.5 ± 0.6 mGy and 3.1 ± 1.7 mGy, respectively ( P = 0.12). At all measured locations, the mean CT number was >300 HU in 120 kV (LMCA 382.9 ± 76.2, distal LAD 341.0 ± 53.9, AA 399.5 ± 76.1) and 50 keV images (LMCA 667.5 ± 139.9, distal LAD 578.1 ± 121.5, AA 700.8 ± 142.5) in the low-contrast cohort, with a 96% increase in CT numbers for 50 keV over 120 kV. The CT numbers were significantly higher ( P < 0.0001) in 50 keV than 120 kV and 100 keV VMI. The CNR was also significantly ( P < 0.0001) higher in 50 keV than 120 kV and 100 keV images in all vessels. Confidence in the assessment of luminal stenosis in the presence of calcific plaque was significantly higher ( P = 0.001) with the addition of 100 keV VMI (median score, 100) than using 50 keV alone (median score, 70) and 120 kV (median score, 70) for reader 1, but no significant differences were seen for reader 2 who had same median scores of 100 for all image types. The confidence in the assessment of luminal stenosis within a stent improved with the use of 100 keV images for both readers (reader 1: median scores for 50 + 100 keV = 100, 50 keV = 82.5, 120 kV = 82.5; reader 2: 50 + 100 keV = 100, 50 keV = 90, 120 kV = 90). There were no significant differences in confidence scores for assessment of luminal stenosis from noncalcific plaques for both readers. The reader-averaged qualitative scores for vascular enhancement and overall image quality were significantly higher for 50 keV VMI than for 120 kV images in both low- and routine-contrast dose cohorts. The image sharpness was nonsignificantly higher at 50 keV VMI than 120 kV images, and the artifact score was comparable for 50 keV VMI and 120 kV images. The noise was higher in 50 keV VMI than in 120 kV images. Conclusions High-pitch ME PCD-CT mode produced diagnostic quality coronary CTA images at low radiation and iodinated contrast doses. The availability of ME VMIs significantly improved the CNR, overall image quality, and confidence in assessment of luminal stenosis in the presence of calcific plaques and stents, and resulted in change of CAD-RADS categories in 9 patients.
Telomerase Expression Related with Poor Immune Response to HCV Core Antigen in Egyptian HCV Patients’ PBMCs
Ibrahim, Iman , El-Sahar, Adel Ahmed, Elrefaei, Mohamed , El-Sheikh, Nabila, Ali, Ola Sayed M. , EL-Sahar, Adel Ahmed

Mayo Clinic

No container title available | February 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2617198/v1 Get It

Abstract Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. This study aimed to assess serum hTERT level and its relation to the progression of liver disease. Also, it aimed to assess the effect of HCV core protein on memory T-cells in HCV patients with or without HCC, and the correlation between memory cells phenotype and the progression of the disease in the same patients. hTERT level in serum was assessed through relative quantitative RT-PCR. Flow cytometric analysis was used to assess T-cells responsiveness (as IFN-γ secretion) before and after stimulation with HCV core protein, and memory CD8+ cells phenotype using several differentiation markers. hTERT was found to be increased in a stepwise manner upon comparing its level in controls, chronic hepatitis patients, cirrhotic patients, and HCC patients. T-cells showed a similar manner of stepwise decrease in response (decreased IFN-γ secretion) in HCC patients compared to HCV patients without HCC and controls. Also, late differentiated memory cells (CD8+ CD27- CD28- CD45RA+CCR7-) were depleted in HCC patients compared to HCV patients without HCC. In conclusion, these results suggest a negative correlation between hTERT and IFN-γ secretion by T- cells in HCV patients and that this relationship along with the depletion of late differentiated memory cells could help the progression of liver disease to HCC.
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Neelapu, Sattva S. , Jacobson, Caron A. , Ghobadi, Armin , Miklos, David B. , Lekakis, Lazaros J. , Oluwole, Olalekan O. , Lin, Yi , Braunschweig, Ira , Hill, Brian T. , Timmerman, John M. , Deol, Abhinav , Stiff, Patrick J. , McSweeney, Peter A., Herrera, Alex F. , Bartlett, Nancy L. , Bot, Adrian A., Shen, Rhine R. , Dong, Jinghui , Singh, Kanwarjit, Miao, Harry , Zheng, Yan , Stiff, Patrick J , Flinn, Ian W , Farooq, Umar , Goy, Andre Henri , Munoz, Javier L , Herrera, Alex F , Bartlett, Nancy L , Oluwole, Olalekan O , Miklos, David B , Ghobadi, Armin , Reagan, Patrick Michael , Flinn, Ian W. , Muñoz, Javier , Siddiqi, Tanya , Chavez, Julio C , Bot, Adrian , Kim, Jaeyeon , Locke, Frederick L.

Mayo Clinic

Blood | February 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2022018893 | PMID 36821768 Get It

In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we aimed to assess survival and safety in ZUMA-1 after 5 years of follow-up. Eligible adults with refractory LBCL (diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma) received lymphodepleting chemotherapy followed by axi-cel infusion targeted at 2×106 cells/kg. Investigator-assessed response, updated survival, safety, and pharmacokinetic outcomes were assessed in treated patients. The objective response rate in the 101 treated patients was 83% (58% complete response rate), and with a median follow-up of 63.1 months, responses were ongoing at data cutoff in 31%. Median overall survival (OS) was 25.8 months and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91%. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. ClinicalTrials.gov, number NCT02348216